Pricing Log in Create free account

Regeneron Pharmaceuticals, Inc. (REGN) vs Vertex Pharmaceuticals Incorporated (VRTX)

Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated are both Biotechnology companies. Vertex Pharmaceuticals Incorporated is the larger, with a market value of $137.5B against $93.4B — 1.5× the size. Regeneron Pharmaceuticals, Inc. trades at the lower P/E: 19.2× against 34.6×. Regeneron Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 18.6% against 10.5%. Vertex Pharmaceuticals Incorporated has the higher net margin (30.7% vs 28.5%) and the higher return on invested capital (14.9% vs 11.6%). Across the 22 metrics below, Regeneron Pharmaceuticals, Inc. leads on 12 and Vertex Pharmaceuticals Incorporated on 10.

Valuation

Metric REGN VRTX Biotechnology median
P/E 19.22 34.57 10.26
P/S 5.44 10.60 9.18
P/B 2.74 6.57 2.05
Price to free cash flow 25.31 42.87 24.81
EV/EBITDA 16.00 29.68 0.65
EV/Sales 5.09 10.41 8.98
Earnings yield 5.20% 2.89% (34.89%)
Free cash flow yield 3.95% 2.33% (24.52%)

Profitability

Metric REGN VRTX Biotechnology median
Gross margin 85.77% 85.53% 65.16%
Operating margin 28.79% 33.23% 0.00%
Net margin 28.51% 30.70% 0.00%
Free cash flow margin 21.47% 24.73% 0.00%
Return on equity 14.95% 20.80% (50.12%)
Return on assets 11.39% 13.81% (45.60%)
Return on invested capital 11.61% 14.86% 0.00%

Growth

Metric REGN VRTX Biotechnology median
Revenue growth (TTM) 18.59% 10.48% 6.26%
EPS growth (last fiscal year) 8.19% 836.54% 29.88%
Revenue growth, 5-year CAGR 11.04% 14.10% 9.75%
Net income growth, 5-year CAGR 5.10% 7.83% 0.00%

Health

Metric REGN VRTX Biotechnology median
Debt to equity 0.06 0.17 0.00
Current ratio 3.35 2.34 4.89
Net debt to EBITDA (1.43) (1.51) 1.01

Dividend

Metric REGN VRTX Biotechnology median
Dividend yield 0.41% — 0.41%
Payout ratio 0.08 — —

Size

Metric REGN VRTX Biotechnology median
Market cap 93.39b 137.54b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack